Smallpox Vaccination Plan Is 'Kaput'--Or Is It?

Frontlines | Smallpox Vaccination Plan Is 'Kaput'--Or Is It? On Dec. 14, 2002, the Bush Administration announced its plan to vaccinate within a 30-day period about 400,000 to 500,000 healthcare workers and "other critical personnel" against smallpox.1 That plan fizzled amid concerns about possible serious adverse reactions and confusion about who could be vaccinated safely.2 By Oct. 10, the Centers for Disease Control and Prevention (CDC) Web site indicated that only 38,542 people are v

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

On Dec. 14, 2002, the Bush Administration announced its plan to vaccinate within a 30-day period about 400,000 to 500,000 healthcare workers and "other critical personnel" against smallpox.1 That plan fizzled amid concerns about possible serious adverse reactions and confusion about who could be vaccinated safely.2

By Oct. 10, the Centers for Disease Control and Prevention (CDC) Web site indicated that only 38,542 people are vaccinated nationwide, but that 291,400 vaccine doses had been shipped to the states. About a week later, USA Today reported that a CDC official said the plan "has stopped."3 Not so, wrote CDC Director Julie Gerberding in a letter published in the paper's Oct. 23 issue. It "continues," she wrote, but now, "the vaccination program is only one element of smallpox preparedness."

CDC spokesman Tom Skinner elaborated, saying that the agency is educating clinicians to diagnose the disease, training public health officials and epidemiologists to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Myrna Watanabe

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours